Danaher acquires Masimo

Danaher Corp has signed a definitive agreement to acquire Masimo Corp for an enterprise value of approximately $9.9 billion. The agreement stipulates a cash payment of $180 per share for all of Masimo's outstanding shares. This acquisition reflects Danaher's strategic push to augment its diagnostics segment with advanced patient monitoring technologies provided by Masimo.

Masimo, known for its innovations in pulse oximetry and patient monitoring, predominantly services acute care settings. Post-acquisition, Masimo will function as a standalone company within Danaher's Diagnostics segment. This aligns it alongside existing subsidiaries like Radiometer and Beckman Coulter Diagnostics, thereby enriching the segment with Masimo's specialized diagnostic solutions.

Danaher's leadership has endorsed the acquisition as a significant expansion of their diagnostic capabilities. Rainer M. Blair, Danaher's president and CEO, acknowledged Masimo's contribution to enhancing patient outcomes, particularly in critical care settings. The integration of Masimo’s technologies with Danaher's global infrastructure is projected to broaden Masimo's market reach and foster innovation in patient monitoring solutions.

The financial underpinnings of the deal indicate that the acquisition will be completed with a mix of cash reserves and debt financing. The estimated transaction multiple stands at 18 times Masimo's projected 2027 EBITDA. Danaher forecasts that the deal will boost its adjusted diluted net earnings per share by $0.15 to $0.20 in the first fiscal year post-completion. Furthermore, Masimo is expected to generate over $530 million in EBITDA by 2027 under Danaher's stewardship.

The acquisition is slated for completion in the second half of 2026, contingent upon regulatory and shareholder approvals. Market observers will be watching closely to see how this integration impacts Danaher's positioning in the competitive health technology sector. The successful closure of this transaction could set a precedent for future consolidations within the diagnostics field, influencing capital allocations and competitive strategies in the industry.